Publications

15 posts

GTC at ASH 2021

GTC is excited to be exhibiting at ASH for the first time and look forward to meeting people in person.  Our booth # 3440 and would like you will stop by and say hello.   If you would like to schedule a meeting fill out the form below  We have four abstracts being presented at ASH – here is […]

Read More

GTC scientists contribute to major study published in Journal of Clinical Oncology: Prediction of outcome in CLL patients

GTC scientists contribute to major study published in Journal of Clinical Oncology: Prediction of outcome in CLL patients

GTC scientists collaborate with the NIH on a study just published in the Journal of Clinical Oncology. The publication is titled: Prediction of outcome in CLL patients treated with ibrutinib: development and validation of a four-factor prognostic model. You can read the article here (subscription required). Abstract: PURPOSE Randomized trials established the superiority of ibrutinib-based […]

Read More

GTC research is being presented at ASCO 2020

GTC research is being presented at ASCO 2020

GTC research is being presented at ASCO 2020 in the following three abstracts. 1. FGFR expression, fusion and mutation as detected by NGS sequencing of DNA and RNA. * 2. Measuring PD-L1 mRNA expression using targeted next generation sequencing and correlation with interferon pathway activation genes in lung and colorectal cancers. * 3. Bimodal ntrk […]

Read More

Study shows that RNA Plus DNA profiling significantly enhanced Drug Matching

RNA Plus DNA profiling significantly enhanced Drug Matching

Recent study published in Nature Medicine (Rodon et al, Nature Medicine volume 25, pages 751–758, 2019) showed that molecular profiling using both DNA and RNA significantly enhanced therapy recommendation and patient outcome.  A third of the studied patients got drug therapy recommendation when both RNA and DNA testing was performed. Genomic testing cooperative (GTC) offers […]

Read More

Acute Lymphoblastic Leukemia | Just published: A consensus of North American experts

Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts The vast majority of adults with acute lymphoblastic leukemia (ALL) achieve remission with standard chemotherapy regimens, but many of these patients ultimately relapse and die from leukemia. In these patients, relapse occurs despite achievement of morphologic remission (ie, […]

Read More

Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers | ASH ANNUAL MEETING ABSTRACT

Dr. Albitar’s molecular work is presented at the ASH meeting in oral and poster presentations. Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers of Drug Resistance in CLL Patients Treated with Ibrutinib Program: Oral and Poster Abstracts | Monday, December 3, 2018: 11:45 AM Type: Oral Session: 642. CLL: Therapy, excluding Transplantation: Advances […]

Read More

Acute Myeloid Leukemia | ASH Annual Meeting Abstract

Acute Myeloid Leukemia

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster I Molecular Epidemiologic Associations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) within the United States Dr. Albitar’s molecular work is presented at the ASH meeting in oral and poster presentations Saturday, December 1, 2018, 6:15 PM-8:15 PM | Hall GH (San Diego Convention Center) Background: Acute […]

Read More

Deep Sequencing

NGS innovation

Deep Sequencing of Cell-Free Peripheral Blood DNA as a Reliable Method for Confirming the Diagnosis of Myelodysplastic Syndrome. BACKGROUND: Demonstrating the presence of myelodysplastic syndrome (MDS)-specific molecular abnormalities can aid in diagnosis and patient management. We explored the potential of using peripheral blood (PB) cell-free DNA (cf-DNA) and next-generation sequencing (NGS). MATERIALS AND METHODS: We […]

Read More